Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Resected Pancreatic Cancer

Trial Name: A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

Protocol ID: RTOG 0848

Eligibility:

Eligibility:
·         Histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e. removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy.
·         Age > 18.
·         Must meet required laboratory values.
·         Women of childbearing potential and male participants must practice adequate contraception.
Ineligibility
·         Patients with non-adenocarcinomas, adenosquamous carcinomas, islet cell (neuroendocrine) tumors, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct, and ampullary carcinomas.
·         Patients managed with a total pancreatectomy, a distal pancreataectomy, or central pancreatectomy.
·         Prior systemic chemotherapy for pancreas cancer; note that prior chemotherapy for a different cancer is allowable.
·         Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.
·         Previous history of invasive malignancy (except non-melanoma skin cancer) unless the patients has been disease free for at leas 2 years prior to study entry (Patients with a previous history of carcinoma in situ are eligible.
·         Pregnant or lactating women.
·         Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.

Enrollment: Enrollment: 950 participants

Benefits:

Taking part in this study may or may not make your health better. It has been proven that gemcitabine will reduce the chance that this cancer will come back and that this will increase your lifespan. It is not proven whether the addition of erlotinib to gemcitabine or the addition of radiation and fluoropyrimidine following gemcitabine will reduce the risk of pancreatic cancer recurring for patients with pancreatic cancer that has already been removed. Based on other studies there are reasons to believe that these treatments may be helpful and this trial is being done to try to find out whether they really are. We do know that the information from this study will help researchers learn more about the treatment of pancreatic cancer. This information could help future cancer patients.

Contact:

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Jul 15, 2010

Updated: Jan 18, 2013

« Return to Trials